AI Research Solution for Due Diligence

ZBrain’s AI research solution for due diligence is designed to enhance your due diligence assessments. From financial performance and regulatory compliance to operational efficiency and market position, this solution covers all critical areas, allowing you to make data-driven decisions.

Trusted By Leading Enterprises

Features of Our Due Diligence Solution

Personalized Customer Engagement

Automated Data Collection

The solution gathers both public and private data like financial records, company reports and metrics, internal documents, and regulatory data, providing you with valuable insights for informed decision-making.

Quality Control and Assurance

Advanced Data Analysis

The solution conducts a comprehensive analysis of financial, legal, operational, and other significant data, identifying key insights and potential risks to guide your due diligence processes effectively.

Quality Control and Assurance

Customizable Reports

Generate tailored due diligence reports that meet your specific requirements and preferences, ensuring that you have access to the information you need in a format that suits your workflow.

Personalized Customer Engagement

Risk Assessment

Utilizing advanced generative AI algorithms, the solution analyzes vast amounts of data to flag potential issues early on, saving you valuable time and resources while ensuring thorough due diligence.

Quality Control and Assurance

Real-time Insights

Gain immediate access to critical data points and market trends, enabling you to translate them into actionable insights that inform your investment decisions with confidence and precision.

Quality Control and Assurance

Integration Capabilities

Seamlessly incorporate our AI solution into your current workflows by leveraging our robust APIs and SDKs. This ensures a smooth integration process with your existing infrastructure, minimizing disruptions.

Benefits of Our Due Diligence Solution

Personalized Customer Engagement

Enhanced Decision-making

Gain deeper insights and understanding of potential investment opportunities and risks, enabling more informed and confident decision-making.

Personalized Customer Engagement

Improved Accuracy

The AI solution enhances the accuracy and reliability of your due diligence process, reducing the risk of oversight or error.

Personalized Customer Engagement


The solution automates time-consuming research tasks and streamlines your due diligence processes, allowing you to focus on strategic decision-making.

Personalized Customer Engagement

Enhanced Data Security

ZBrain ensures your data’s security and confidentiality with secure handling, encryption, access control, and compliance with industry standards.

Our Partners

Industries We Serve

Financial Services




Real Estate

Government and Public Sector

Retail and Consumer Goods

Legal and Consulting

Sample Due Diligence Research Report

Due Diligence research for 

Genext Biotechnology

The objective of this report is to provide an initial research report done using AI on an organization.

Generated using 


Years in Business
Company Age: 20

About Genext Biotechnology
Genext Biotechnology is a pioneering company at the forefront of developing innovative solutions in the field of biotechnology. With a strong commitment to research and development, Genext Biotechnology focuses on harnessing the power of science to address some of the most challenging medical and environmental issues facing our world today.

Our team consists of world-class scientists, researchers, and professionals who are dedicated to pushing the boundaries of biotechnology. Through our collaborative efforts, we aim to create groundbreaking therapies and technologies that can significantly improve human health and the sustainability of our planet.

At Genext Biotechnology, we believe in the importance of operating at the intersection of rigorous scientific research and ethical responsibility. Our approach is rooted in a deep understanding of the biological systems we study, combined with cutting-edge technological advancements. This allows us to develop solutions that are not only effective but also safe and environmentally friendly.

Our portfolio includes a diverse range of projects, from developing novel drugs and therapies to combat various diseases, to creating sustainable biotechnological applications for agriculture and industry. Each project is guided by our commitment to excellence, innovation, and the well-being of communities worldwide.

As a company, we are driven by the vision of a healthier and more sustainable future for all. We are constantly exploring new frontiers in biotechnology, seeking to unlock the potential that lies within the biological sciences for the benefit of humanity and the earth. Genext Biotechnology is committed to being a leader in the biotech industry, contributing to the advancement of science and the betterment of society.

Company Industry: Biotechnology

Online Reviews

Positive Feedback Summary

– Genext Biotechnology is a drug discovery and development company committed to making cancers curable, focusing on cancer therapeutics with a lead program targeting proteins crucial for cancer cell adaptation, drug resistance, and metastasis.

– The company is developing highly selective small-molecule inhibitors for the treatment of prostate cancer, breast cancer, leukemia, and potentially other cancers in combination with different therapeutics. Their latest drug candidate is anticipated to enter clinical trials within a year.

– Apart from its lead program, Genext is also working on drugs targeting two other unique cancer targets, expanding its portfolio and potential impact on cancer treatment.

– Genext Biotechnology has a robust policy on Financial Conflicts of Interest (FCOI) in Public Health Service funded research, ensuring transparency and objectivity in their research projects by managing any financial conflicts that may arise.

– The company has established a comprehensive framework, adhering to federal regulations, for disclosing, managing, and reporting significant financial interests to prevent any bias in the design, conduct, or reporting of research. This includes mandatory training for investigators and regular updates to ensure compliance.

– Public accessibility to information regarding financial conflicts of interest is guaranteed, with detailed disclosures available on a publicly accessible website or provided promptly upon request, highlighting the company’s commitment to transparency and accountability.

Negative Feedback Summary

– Some users might have experienced difficulty navigating the site due to a lack of direct links or clear guidance on how to access specific information, such as detailed descriptions of research projects or product development updates.

– The extensive use of technical jargon without layman-term explanations could alienate non-specialist visitors, leading to frustration and negative feedback.

– The website’s policy sections, particularly around financial conflicts of interest (FCOI), are comprehensive but may be overly complex for the average reader, possibly causing confusion and dissatisfaction.

– The repetition of content in some areas might have led to boredom or the impression that the site lacks depth in information variety.

– A potential lack of interactive features or user engagement opportunities (e.g., forums, comment sections) may make the site feel static and unresponsive to users accustomed to more dynamic online experiences.

– Users might have expected more current updates or news related to the company’s progress and achievements, finding the provided content outdated or insufficiently informative.

– The absence of easily accessible contact information or a straightforward way to engage with Genext Biotechnology personnel could contribute to negative user experiences.

– Some visitors might find the website’s design or layout unappealing or hard to navigate, impacting their overall satisfaction negatively.

Sentiment Analysis of Online Reviews
The provided data encompasses information from Genext Biotechnology, Inc.’s website and LinkedIn profile, focusing on their commitment to making cancers curable through drug discovery and development, particularly in the realm of highly selective small-molecule inhibitors targeting proteins involved in cancer cell adaptation, resistance, and metastasis. The tone of the content is optimistic and forward-looking, highlighting the company’s efforts in advancing towards clinical trials for their drug candidates and their engagement in public health service funded research with a stringent policy on financial conflicts of interest (FCOI) to ensure objectivity and integrity in their research endeavors.

The sentiment conveyed through the description of their lead program and the anticipation of clinical trials within a year suggests a positive outlook on their potential impact on treating incurable types of prostate cancer, breast cancer, and leukemia. This optimism is further supported by the detailed FCOI policy aimed at maintaining transparency and ethical standards in research, which could instill confidence in stakeholders regarding the company’s commitment to responsible and unbiased scientific inquiry.

Moreover, the company’s active engagement with the community and stakeholders, as evidenced by their presentation at the Best of Keiretsu Forum Virtual Investment Showcase and their detailed public accessibility policy for disclosing financial conflicts of interest, reflects a proactive approach to communication and transparency. This openness not only reinforces the positive sentiment surrounding their scientific endeavors but also underscores their dedication to ethical practices and accountability in the biotechnology research field.


The provided text from the website [](/) does not provide any specific information about a company’s funding or financial data. It seems like there was an error in the search as it states “No items found”. There are no details available about any company, its funding, or other important data.

News Summary

Genext Biotechnology, Inc. is a drug discovery and development company with a strong focus on creating therapeutics for cancer. The company has been active in the field, achieving significant milestones and engaging in various research activities to advance its mission of making cancers curable. Below is a detailed summary of the news related to Genext Biotechnology based on the provided data:

### Research and Development Achievements

– **June 2023**: An article published in Nucleic Acids Research highlighted the use of Genext’s Mediator kinase inhibitors and a novel CDK8/19 degrader to elucidate the molecular functions of CDK8 and CDK19.

– **February 2023**: Genext was granted a US patent (11,572,369) for new selective Mediator kinase inhibitors designed for cancer therapy.

– **December 2022**: A study titled “Dual therapeutic targeting of CDK8/19 and mTOR in triple negative breast cancer” was presented at the San Antonio Breast Cancer Symposium, showcasing Genext’s collaborative efforts in cancer research.

### Grants and Funding

– Genext has successfully secured grants to support its research programs, including:

  – A Phase I SBIR grant from the National Cancer Institute for its breast cancer drug development program (September 2022).

  – A Translational Science Award from the Department of Defense for prostate cancer drug development (March 2022).

  – A Phase II SBIR grant from the National Cancer Institute for its prostate cancer drug development program (June 2020).

### Leadership and Partnerships

– **July 2022**: Dennis Goldberg, PhD, joined Genext as Chief Executive Officer, bringing over 30 years of leadership experience in the pharmaceutical and biotechnology industries.

– **August 2021**: George Wilding, MD, assumed the position of Chief Medical Officer, strengthening the company’s executive team.

### Scientific Contributions and Collaborations

– Genext has been involved in numerous studies and publications that contribute to the understanding and treatment of cancer:

  – **August 2022**: A study reported in Proc Natl Acad Sci USA demonstrated that Genext’s Mediator kinase inhibitors sensitize HER2-positive breast cancers to HER2-targeting drugs, indicating a potential strategy to overcome drug resistance.

  – **April 2022**: A study presented at the Annual Meeting of the American Association for Cancer Research highlighted the suppression of primary and metastatic growth of castration-resistant prostate cancer through the inhibition of CDK8/19 Mediator kinase.

### Intellectual Property and Licensing

– Genext has been granted multiple US patents covering the composition of matter of selective Mediator kinase inhibitors and their uses for cancer therapy, underscoring the company’s commitment to innovation and securing its intellectual property rights.

### External Collaborations

– Genext Biotechnology utilized Enzymlogic’s KINETICfinder® platform for kinetic profiling, which helped identify a new class of quinoline-based Genextin derivatives with therapeutic potential against cancer. This collaboration underscores Genext’s approach to leveraging advanced technologies for drug discovery.

### Community Engagement and Recognition

– Genext Biotechnology received a “big check” investment from SCRA Technology Ventures’ SC Launch program in April 2014, signifying community and investor confidence in the company’s potential to impact cancer treatment.

Overall, Genext Biotechnology, Inc. has demonstrated a strong commitment to advancing cancer therapy through rigorous research, strategic collaborations, securing intellectual property rights, and attracting investments and grants to fuel its innovative drug development programs.

Competitive Analysis

Name of the company: Berlitz Corporation

About the company: Berlitz Corporation is a global education company that offers language training, cultural training, and related services to individuals, businesses, and government agencies. The company provides a wide array of language learning courses, including online classes, private lessons, and group courses in various languages such as English, Spanish, French, German, Arabic, Korean, Mandarin, Portuguese, Italian, Japanese, and more. Berlitz employs a distinctive teaching method known as the Berlitz Method, focusing on immersive language learning techniques to enhance communication skills effectively.

Brief summary about people involved: The article features Karolina Assi as the author, who has contributed a blog post titled “67 ways to say sorry in English to someone, sincerely with grace.” The post is intended for English learners to improve their apology expressions across different contexts—showing how saying sorry varies depending on the situation. It covers various scenarios including apologizing for mistakes, expressing sympathy, and asking for forgiveness in both personal and professional settings.

Any other critical information: Berlitz’s offerings extend beyond individual language courses. They cater to kids and teens through school programs and online courses, offer corporate training including language and culture training, and have specialized programs for government training. The company emphasizes accessibility in learning languages and improving communication skills for a broad audience, aiming to strengthen relationships and foster better understanding across different cultures. Berlitz encourages continuous learning through its blog, which contains articles on various topics related to language and communication, inviting readers to expand their knowledge.

Name of the company: Craft CMS

About the company: Craft CMS is a content management system that focuses on flexibility and ease of use for administrators while offering powerful development tools for creating custom digital experiences.

Brief summary about people involved:

– **piotrpog**: Reported an issue related to data submission errors occurring randomly during various activities like saving entries, adding fields, or installing plugins. Initially experienced in a Windows-based Craft CMS installation.

– **brandonkelly**: Responded to the issue suggesting that the error occurs due to mismatch between CSRF token param and CSRF cookie. Advised trying different browsers or clearing cookies. Later acknowledged potential issues with multiple Craft installs on localhost causing cookie conflicts. Suggested configuring unique CSRF tokens or hostnames for each local site to mitigate the problem.

– **intoeetive**, **simeon-smith**, **amityweb**, **MichaelCaraccio**, **jayhlee**, **stenvdb**, **Kimixi**, **controlnocontrol**, **iamkeir**, **mattstein**, **BenMenking**, **Abdulkadiragoliya**: Various community members who contributed to the discussion with their experiences, suggestions, and confirmations of similar issues or resolutions. Topics ranged from CSRF token handling, browser switching, caching issues, and specific configurations to resolve or work around the problem.


Any other critical information: 

– The issue titled “Unable to verify your data submission” (#3330) was extensively discussed, with community members reporting similar problems and solutions. The discussion included technical aspects like CSRF token validation, effects of browser caching, and configurations to avoid conflicts when running multiple instances of Craft CMS locally.

– Brandon Kelly, presumably a member of the Craft CMS team, played a significant role in troubleshooting and proposing solutions, indicating active involvement from the company in community support.

– The discussion highlighted common challenges developers face regarding session management, form submissions, and CSRF protection in web development, especially in complex or multi-environment setups.

Name of the company: Indeed

About the company: Indeed is a global employment-related search engine for job listings. It offers a variety of services including job search, company reviews, salary comparisons, and career advice. The website acts as a comprehensive resource for individuals looking to find work, learn about potential employers, and gather insights into various career paths and salary expectations. Indeed encourages users to review their privacy policy, cookie policy, and terms of use.

Brief summary about people involved: The article referenced is authored by the Indeed Editorial Team, suggesting it’s a collaborative effort by professionals associated with Indeed to provide career guidance. This specific piece focuses on how to write a supporting letter, offering a template and example to help users effectively support individuals, causes, or organizations in a professional context.

Any other critical information: The article details the importance of a supporting letter, describing it as a personal endorsement for a person, cause, or idea. It provides step-by-step guidance on writing a supporting letter, starting from identifying the purpose and audience, brainstorming ideas, organizing evidence, and drafting the letter, to proofreading and submission. The article emphasizes the persuasive nature of a supportive letter and its role in influencing the reader’s decision positively. A template and an example are provided to aid readers in crafting their letters. Additionally, the relevance of maintaining a professional tone and the necessity of proofreading to ensure credibility are highlighted.

Market Size 

The global biotechnology market was valued at USD 372.8 billion in 2021. It is expected to witness significant growth, reaching approximately USD 1,345.0 billion by the year 2030. This projected growth will occur at a compound annual growth rate (CAGR) of 15.5% from 2022 to 2030. The expansion of the market is primarily driven by the increasing prevalence of chronic illnesses, rising demand for agriculture-based product offerings, and favorable government initiatives in emerging markets. Additionally, the market is expected to benefit from technological advancements and the approval and introduction of new products.




  1. Title: CDK8-CDK19 selective inhibitors and their use in anti-metastatic and …

   Patent Code: US10993945B2

   Description: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related …

  1. Title: CDKI pathway inhibitors and uses thereof

   Patent Code: US8598344B2

   Description: The invention relates to compounds for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related diseases.

  1. Title: CDKI pathway inhibitors and uses thereof

   Patent Code: US9409873B2

   Description: The invention relates to the compounds and methods for inhibiting the Cyclin-Dependent Kinase Inhibitor (CDKI) pathway. More particularly, the invention relates to compounds and methods for inhibiting the CDKI pathway for studies of and intervention in senescence-related and other CDKI-related …

  1. Title: Quinoline-based compounds and methods of inhibiting CDK8/19

   Patent Code: US11014906B2

   Description: Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a …

  1. Title: High-content screening for drugs against cancer and age-related diseases

   Patent Code: US8592147B2

   Description: The invention relates to methods for high-throughput screening for compounds that modulate cell growth or promoter activity. The invention provides the use of cell lines with properly regulated promoter-reporter expression, suitable for high-throughput screening. More particularly, the invention …

  1. Title: Cell-based methods for measuring activity of a protein inhibitor

   Patent Code: US10584369B2

   Description: The invention provides a method for determining the activity of an inhibitor of a target protein that has a deleterious effect on cell growth. The principle of the claimed method is that a compound that inhibits the function of an overexpressed protein will relieve the detrimental effect of such …

  1. Title: Bicyclic pyridine compositions and methods of using the same for cancer therapy

   Patent Code: US11572369B2

   Description: Disclosed herein are bicyclic pyridines, such as thienopyridine, pyrrolopyridine, furopyridine compounds, and methods for treating cancers.


Filename: Genext Biotechnology Marketing and Sales Summary [1].pdf


Genext Company is developing SNX631-6, an oral first-line therapy for Prostate Cancer patients who have failed advanced androgen deprivation therapy (Castration Resistant Prostate Cancer – CRPC). The company strategy for Genext is to exit at initiation of Phase 1/2 clinical trials at two clinical sites or after completion of human proof-of-concept studies in CRPC patients. An exit at initiation of the Phase 1/2 clinical trials will have a lower value than an exit upon completion but will reduce the risk to investors.

The market for CRPC was $10.9 billion in 2022 and is projected to grow to $22.5 billion in 2032. The unmet need in CRPC is significant, and the market size for this cancer is of substance. When approved, SNX631-6 should rapidly become the standard of care for CRPC, and post-approval clinical studies will expand the indication to earlier stages of prostate cancer in combination with androgen deprivation therapy, thereby significantly increasing the market opportunity.

Recent oncology deals include Bristol-Myers acquiring Turning Point Therapeutics for $4.1 billion, Novartis acquiring Endocyte for $2.1 billion, and Menarini acquiring Stemline for $667 million. Recent oral drug deals include Takeda acquiring Nimbus Lakshmi, Inc., a subsidiary of Nimbus, for its tyrosine kinase 2 inhibitor after a Phase 2b clinical study in moderate to severe psoriasis.

Filename: Genext Biotechnology Marketing and Sales Summary.pdf


Genext Company is developing SNX631-6, a once-daily oral first-line therapy for Prostate Cancer patients who have failed advanced androgen deprivation therapy (Castration Resistant Prostate Cancer – CRPC). The company’s strategy is to exit at initiation of Phase 1/2 clinical trials at two clinical sites or after completion of human proof-of-concept studies in CRPC patients. An exit at initiation of the Phase 1/2 clinical trials will have a lower value than an exit upon completion but will reduce the risk to investors.

The market for CRPC was $10.9 billion in 2022 and is projected to grow to $22.5 billion in 2032. The unmet need in CRPC is significant, and the market size for this cancer is of substance. When approved, SNX631-6 should rapidly become the standard of care for CRPC, and post-approval clinical studies will expand the indication to earlier stages of prostate cancer.



Ready to explore the power of AI in due diligence? Book a demo now to see our solution in action.